Corrales and coworkers demonstrated that, in melanoma cells, a decrease in sensitivity to MAPK/ERK inhibitors is accompanied by higher activity of the PI3K/Akt pathway, which is particularly evident in mesenchymal-like cells supporting their acquisition of stem-like features [207]. The gene discussed is AKT1; the disease is melanoma.